Cabozantinib for Hepatocellular Carcinoma

Cabozantinib is a new biological treatment called a tyrosine kinase inhibitor or TKI. It stops signals that cancer cells use to divide and grow. It is currently being considered as a treatment option for patients who fail primary treatment with sorafenib.